Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (RMPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL) Meeting Abstract
| Authors: | Omuro, A. M. P.; DeAngelis, L. M.; Karrison, T.; Bovi, J. A.; Rosenblum, M.; Corn, B. W.; Correa, D.; Wefel, J. S.; Aneja, S.; Grommes, C.; Schaff, L.; Waggoner, S. E.; Lallana, E. C.; Werner-Wasik, M.; Iwamoto, F.; Robinson, T. J.; Donnelly, E.; Struve, T.; Won, M.; Mehta, M. P.; NRG |
| Abstract Title: | Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (RMPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368301196 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.2501 |
| Notes: | Meeting Abstract: 2501 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
